Istituto di Genetica Molecolare, "Luigi Luca Cavalli-Sforza", Consiglio Nazionale delle Ricerche, via Abbiategrasso 207, 27100, Pavia, Italy.
Cardiovascular Biology Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149, Trieste, Italy.
J Exp Clin Cancer Res. 2020 Dec 7;39(1):275. doi: 10.1186/s13046-020-01753-1.
Alternative splicing (AS) is a pervasive molecular process generating multiple protein isoforms, from a single gene. It plays fundamental roles during development, differentiation and maintenance of tissue homeostasis, while aberrant AS is considered a hallmark of multiple diseases, including cancer. Cancer-restricted AS isoforms represent either predictive biomarkers for diagnosis/prognosis or targets for anti-cancer therapies. Here, we discuss the contribution of AS regulation in cancer angiogenesis, a complex process supporting disease development and progression. We consider AS programs acting in a specific and non-redundant manner to influence morphological and functional changes involved in cancer angiogenesis. In particular, we describe relevant AS variants or splicing regulators controlling either secreted or membrane-bound angiogenic factors, which may represent attractive targets for therapeutic interventions in human cancer.
选择性剪接 (AS) 是一种普遍存在的分子过程，可从单个基因产生多种蛋白质异构体。它在发育、分化和组织稳态维持中起着至关重要的作用，而异常的 AS 被认为是多种疾病的标志，包括癌症。癌症特异性 AS 异构体既可以作为诊断/预后的预测生物标志物，也可以作为抗癌治疗的靶点。在这里，我们讨论了 AS 调控在癌症血管生成中的作用，癌症血管生成是支持疾病发展和进展的一个复杂过程。我们认为，AS 调控以特定且非冗余的方式发挥作用，影响癌症血管生成中涉及的形态和功能变化。具体而言，我们描述了控制分泌型或膜结合型血管生成因子的相关 AS 变体或剪接调控因子，这些因子可能是人类癌症治疗干预的有吸引力的靶点。
